Talphera, Inc.
TLPHAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 13, 2026 | H.C. Wainwright | Brandon Folkes | $3.00(+114%) | $1.40 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jan 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 7, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 25, 2023 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Aug 18, 2023 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.06| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.06 | $-0.06 | — | — |
| May 13, 2026 | $-0.04 | $-0.07 | — | — |
| Mar 23, 2026 | $-0.06 | $-0.07 | — | $580.0K |
| Nov 12, 2025 | $-0.11 | $-0.07 | $1.0K | — |
| Aug 14, 2025 | $-0.10 | $-0.12 | — | — |
| May 14, 2025 | $-0.10 | $-0.17 | $27.0K | — |
| Mar 31, 2025 | $-0.07 | $-0.21 | — | — |
| Nov 13, 2024 | $-0.13 | $-0.20 | — | — |
News
SAN MATEO, Calif., Nov. 4, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Thursday, November 12, 2026 at 4:30 p.m.
Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends. Analyst Recommendations This is a summary of current
Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C.
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments of $17.1 million at June 30, 2026 Conference call and webcast to be held on Wednesday A…